Tepid 4Q for Indian firms amid ANDA trickle, currency woes?
This article was originally published in Scrip
Executive Summary
Fourth quarter earnings seasons in India may by and large be a lukewarm affair, with a slowdown in the number of ANDA approvals, currency headwinds and continuing FDA scrutiny at domestic sites expected to rein in growth across a clutch of Indian firms.